Should everybody be taking Ozempic?

Should everybody be taking Ozempic?

  • Af
  • Episode
      1944
  • Published
      11. dec. 2025
  • Forlag
0 Anmeldelser
0
Episode
1944 of 1949
Længde
26M
Sprog
Engelsk
Format
Kategori
Fakta

It's estimated that as many as 10 per cent of adults in Canada use a GLP-1 type drug like Ozempic. The prescription medicine is used for type 2 diabetes management and increasingly prescribed off-label for weight loss. And this month, for the first time, the World Health Organization has conditionally recommended GLP-1 drugs for the long-term treatment of obesity.

But while these drugs have been called a game-changing tool to manage a complex and stigmatized health condition, there’s also a lot of questions about the potential negative impact.

With Ozempic’s patent set to expire soon in Canada, and more affordable generic options about to hit the market, a lot more people you know could end up on a weight-loss drug.

Today we bring you the rise and risks of GLP-1s with help from Dylan Scott. He is a Senior Correspondent at Vox who covers health.

For transcripts of Front Burner, please visit: https://www.cbc.ca/radio/frontburner/transcripts


Lyt når som helst, hvor som helst

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

  • Lyt og læs så meget du har lyst til
  • Opdag et kæmpe bibliotek fyldt med fortællinger
  • Eksklusive titler + Mofibo Originals
  • Opsig når som helst
Prøv nu
DK - Details page - Device banner - 894x1036
Cover for Should everybody be taking Ozempic?

Other podcasts you might like ...